Search
Semaglutide Treatment Options in Canada
A collection of 85 research studies where Semaglutide is the interventional treatment. These studies are located in the Canada . Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
25 - 36 of 85
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
Completed
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/17/2025
Locations: North AL Health Res, LLC, Huntsville, Alabama +183 locations
Conditions: Non-alcoholic Steatohepatitis
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
Completed
This study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes.
This study will look at how much weight participants lose, and if participants can go from having blood sugar that is higher than normal (prediabetes) to having normal blood sugar.
Semaglutide is compared to a "dummy" medicine. The "dummy" medicine looks like semaglutide but has no effect on the body.
In addition to taking the medicine, participants will have talks with study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of Calgary, Calgary, Alberta +29 locations
Conditions: Obesity
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Recruiting
The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations
Conditions: Diabetic Kidney Disease, Type 1 Diabetes
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
Not Yet Recruiting
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Unity Health Toronto, Toronto, Ontario
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
Completed
This study will look at how CagriSema affects the blood levels of atorvastatin and warfarin. The study will look at the levels of warfarin and atorvastatin in the blood before the participant starts taking CagriSema and if this changes after the participant has taken CagriSema. The study will also investigate the effect of warfarin before and after the participant takes CagriSema and assess if the injection site affects the level of CagriSema in the blood. The study will last for about 8 months.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/09/2025
Locations: Altasciences Company Inc., Mount-Royal, Quebec
Conditions: Obesity
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Active Not Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: University of Alabama - Department of Nutrition Sciences, Birmingham, Alabama +76 locations
Conditions: Diabetes Mellitus, Type 2
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
Completed
This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or "dummy" medicine. W... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +99 locations
Conditions: Obesity
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
Completed
Study to assess the effects of weekly subcutaneous administration of the GLP1-RA semaglutide 2.4mg on kidney function parameters in obese/overweight individuals at high risk of CKD progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: University of Calgary, Calgary, Alberta +12 locations
Conditions: Obesity, Albuminuria
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
Completed
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screening period, 64 weeks of treatment period and 7 weeks of follow up period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Univsty Of AL At Birmingham, Birmingham, Alabama +21 locations
Conditions: Overweight, Obesity
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
Completed
The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants will either get semaglutide tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance. Participants must take one tablet with water every morning on an empty stomach and not eat or drink anything for at least 30 minutes. The study will last for about 3.5-5 years. Participants will have up to 25 clinic visits and 1 phone ca... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/08/2025
Locations: Healthscan Clinical Trials,LLC., Montgomery, Alabama +473 locations
Conditions: Diabetes Mellitus, Type 2
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
Not Yet Recruiting
The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: St. Paul's Hospital, Vancouver, British Columbia +1 locations
Conditions: Kidney Transplant Recipient
A Clinical Trial to Evaluate the Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living with Type 1 Diabetes
Recruiting
The goal of this clinical trial is to learn if Empagliflozin and Semaglutide, individually and combined, added to Automated Insulin Delivery (AID) works to improve time-in-range in adults living with Type 1 Diabetes. It will also evaluate the safety of Empagliflozin and Semaglutide in this context.
The primary hypothesis of this study is :
- The combination therapy of semaglutide and empagliflozin will increase time-in-range compared to placebo when added to AID therapy.
The secondary hypothe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Research Institute of the McGill University Health Centre, Montréal, Quebec
Conditions: Diabetes Type 1
25 - 36 of 85